Compare HRTG & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | XNCR |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 704.5M | 881.9M |
| IPO Year | 2014 | 2013 |
| Metric | HRTG | XNCR |
|---|---|---|
| Price | $23.05 | $11.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $33.50 | $22.33 |
| AVG Volume (30 Days) | 479.7K | ★ 712.4K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 214.43 | 65.36 |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $847,330,000.00 | $125,576,000.00 |
| Revenue This Year | $7.50 | N/A |
| Revenue Next Year | $6.74 | $4.80 |
| P/E Ratio | $19.78 | ★ N/A |
| Revenue Growth | 3.71 | ★ 13.65 |
| 52 Week Low | $16.83 | $6.92 |
| 52 Week High | $31.98 | $18.69 |
| Indicator | HRTG | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 38.27 | 42.24 |
| Support Level | $22.46 | $11.02 |
| Resistance Level | $24.14 | $13.28 |
| Average True Range (ATR) | 1.33 | 0.72 |
| MACD | -0.21 | -0.16 |
| Stochastic Oscillator | 25.27 | 24.53 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance across various states in the U.S. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. The company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, and South Carolina.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.